Rallybio Corp (RLYB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $88.03M
Last updated: Nov 17, 2026 at 11:04 AM ET
Rallybio Corp (RLYB) Financials: Revenue, Profit and Cash Flow
Rallybio reported revenue of $858.00K for the fiscal year ended Dec 31, 2025, up 34.9% from the year before. That year, net income was -$8.98M with a net margin of -1046.4%, operating cash flow was -$29.81M and free cash flow was -$29.81M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$2.73M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $858.00K | +34.9% | 100.0% | -3853.6% | -1046.4% |
| Dec 2024 | $636.00K | N/A | 100.0% | -9511.9% | -9084.1% |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $858.00K | $636.00K | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $26.34K |
| Gross profit | $858.00K | $636.00K | $0 | $0 | $0 | $0 | -$26.34K |
| Research and development | $19.60M | $41.51M | $53.54M | $40.69M | $26.91M | $17.63M | $11.37M |
| Operating income | -$33.06M | -$60.50M | -$78.93M | -$67.88M | -$45.65M | -$25.30M | -$17.64M |
| Net income | -$8.98M | -$57.77M | -$74.56M | -$66.65M | -$47.01M | -$26.45M | -$17.63M |
| EBITDA | -$10.77M | N/A | N/A | N/A | -$45.44M | -$25.00M | -$17.39M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $212.00K | $222.00K | $212.00K | $212.00K | $212.00K | $38.00K | $299.00K | $299.00K | $0 | $228.00K |
| Gross profit | $0 | $0 | $212.00K | $222.00K | $212.00K | $212.00K | $212.00K | $38.00K | $299.00K | $299.00K | $0 | $114.00K |
| Operating income | -$3.42M | -$5.65M | -$8.73M | -$6.41M | -$6.92M | -$10.06M | -$9.67M | -$11.61M | -$12.07M | -$17.04M | -$19.79M | -$21.11M |
| Net income | -$2.73M | $43.66M | -$8.28M | -$5.85M | $16.02M | -$9.70M | -$9.44M | -$11.04M | -$11.47M | -$16.24M | -$19.03M | -$20.24M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $94.00K by $31.28M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $62.26M | $68.11M | $115.62M | $180.44M | $182.19M | $141.86M | $21.61M |
| Current assets | $61.25M | $67.84M | $114.79M | $179.50M | $180.87M | $141.26M | $20.92M |
| Cash and equivalents | $31.37M | $13.90M | $24.49M | $56.96M | $175.33M | $140.23M | $19.46M |
| Total liabilities | $4.30M | $6.45M | $9.44M | $11.12M | $6.58M | $5.86M | $4.75M |
| Short-term debt | $94.00K | $154.00K | $219.00K | $181.00K | N/A | N/A | N/A |
| Shareholder equity | $57.96M | $61.65M | $106.18M | $169.32M | $175.60M | $136.00M | $16.86M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $95.58M | $98.06M | $54.47M | $62.26M | $67.66M | $51.00M | $57.98M | $68.11M | $79.01M | $92.43M | $99.36M | $115.62M |
| Total liabilities | $3.28M | $3.57M | $4.20M | $4.30M | $4.63M | $5.04M | $3.91M | $6.45M | $8.19M | $12.41M | $10.20M | $9.44M |
| Cash and equivalents | $90.69M | $92.85M | $41.30M | $31.37M | $32.12M | $9.45M | $14.78M | $13.90M | $25.32M | $16.67M | $19.30M | $24.49M |
| Shareholder equity | $92.30M | $94.50M | $50.28M | $57.96M | $63.03M | $45.96M | $54.07M | $61.65M | $70.82M | $80.02M | $89.16M | $106.18M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.81M | -$49.28M | -$60.27M | -$57.28M | -$45.53M | -$22.04M | -$15.03M |
| Capital expenditures | $0 | $0 | $12.00K | $54.00K | $333.00K | $137.00K | $188.00K |
| Free cash flow | -$29.81M | -$49.28M | -$60.28M | -$57.34M | -$45.87M | -$22.18M | -$15.21M |
| Share repurchases | $0 | $268.00K | $139.00K | $693.00K | $3.23M | $319.00K | N/A |
| Investing cash flow | $47.27M | $33.49M | $27.66M | -$112.17M | -$2.33M | -$2.07M | -$188.00K |
| Financing cash flow | $16.00K | $5.20M | $143.00K | $51.08M | $82.97M | $144.89M | $31.57M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.28M | $45.92M | -$7.98M | -$4.68M | -$6.55M | -$8.38M | -$10.21M | -$9.86M | -$13.54M | -$10.42M | -$15.46M | -$11.64M |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $12.00K |
| Free cash flow | N/A | N/A | -$7.98M | -$4.68M | -$6.55M | -$8.38M | -$10.21M | -$9.86M | -$13.54M | -$10.42M | -$15.46M | -$11.66M |
Frequently Asked Questions About RLYB
What is Rallybio's annual revenue?
Rallybio reported revenue of $858.00K for the fiscal year ended Dec 31, 2025.
How fast is Rallybio's revenue growing?
Revenue was up 34.9% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Rallybio profitable?
No. Rallybio reported net income of -$8.98M for the fiscal year ended Dec 31, 2025, with a net margin of -1046.4%.
How much free cash flow does RLYB generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$29.81M minus capital expenditures of $0 produced free cash flow of -$29.81M.
How much debt does Rallybio have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $94.00K and cash and equivalents of $31.37M.
RLYB pages: Overview, Earnings, Forecast, Financials, Competitors